BR9609013A - Análogo de nucleosìdeos, e, composto. - Google Patents

Análogo de nucleosìdeos, e, composto.

Info

Publication number
BR9609013A
BR9609013A BR9609013-8A BR9609013A BR9609013A BR 9609013 A BR9609013 A BR 9609013A BR 9609013 A BR9609013 A BR 9609013A BR 9609013 A BR9609013 A BR 9609013A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
compound
nucleoside analog
adenosine
adenosine kinase
Prior art date
Application number
BR9609013-8A
Other languages
English (en)
Inventor
Serge H Boyer
Mark D Erion
Bheemarao G Ugarkar
Original Assignee
Gensia Sicor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Sicor filed Critical Gensia Sicor
Publication of BR9609013A publication Critical patent/BR9609013A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANáLOGOS DE NUCLEOSìDEOS, E, COMPOSTO". Esta invenção diz respeito a inibidores da adenosina cinase e a análogos de nucleosídeo, análogos de nucleosídeo de pirrol[2,3-d] pirimidina e pirazol[3,4-d] pirimidina modificados por C-4^ '^ , tendo atividade como inibidores da adenosina cinase. A invenção também diz respeito à preparação e uso destes inibidores da adenosina cinase no tratamento de doenças cardiovasculares e cerebrovasculares, inflamação e outras doenças que podem ser reguladas mediante aumento da concentração local de adenosina.
BR9609013-8A 1995-06-07 1996-06-07 Análogo de nucleosìdeos, e, composto. BR9609013A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,161 US5674998A (en) 1989-09-15 1995-06-07 C-4' modified adenosine kinase inhibitors
PCT/US1996/010404 WO1996040705A1 (en) 1995-06-07 1996-06-07 C-4' modified adenosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR9609013A true BR9609013A (pt) 1999-12-14

Family

ID=23930844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609013-8A BR9609013A (pt) 1995-06-07 1996-06-07 Análogo de nucleosìdeos, e, composto.

Country Status (24)

Country Link
US (1) US5674998A (pt)
EP (1) EP0832091B1 (pt)
JP (1) JPH11507387A (pt)
KR (1) KR19990022740A (pt)
CN (1) CN1190401A (pt)
AP (1) AP9701165A0 (pt)
AT (1) ATE257841T1 (pt)
AU (1) AU6178396A (pt)
BG (1) BG102163A (pt)
BR (1) BR9609013A (pt)
CA (1) CA2220642A1 (pt)
CZ (1) CZ392797A3 (pt)
DE (1) DE69631330T2 (pt)
EA (1) EA199800009A1 (pt)
HU (1) HUP9802193A3 (pt)
IL (1) IL122335A0 (pt)
IS (1) IS4621A (pt)
MX (1) MX9709859A (pt)
NO (1) NO975585L (pt)
OA (1) OA10639A (pt)
PL (1) PL323904A1 (pt)
SK (1) SK166097A3 (pt)
TR (1) TR199701539T1 (pt)
WO (1) WO1996040705A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
BR9609617B1 (pt) * 1995-07-06 2010-07-27 derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
MXPA02001753A (es) * 1999-08-27 2002-10-23 Ribapharm Inc Analogos de nucleosido de pirrolo [2,3-d]pirimidina.
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
AU1929801A (en) * 1999-12-16 2001-06-25 Alcon Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
CN1372564A (zh) * 2000-02-10 2002-10-02 三井化学株式会社 选择性制备1－磷酸化糖衍生物端基异构体的方法和制备核苷的方法
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JP5048520B2 (ja) 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
JP2009504677A (ja) * 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
EP2402334B1 (en) 2006-02-02 2016-06-29 Millennium Pharmaceuticals, Inc. Inhibitors of E1 Activating Enzymes
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ613219A (en) * 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2010132110A1 (en) 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
NZ714415A (en) 2013-06-26 2017-09-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
WO2017024310A1 (en) 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
MX2022001467A (es) 2019-08-08 2022-05-06 B C I Pharma Derivados quinolina como inhibidores de proteína quinasa.
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455420A (en) * 1983-01-13 1984-06-19 Hoffmann-La Roche Inc. 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
CA2100863A1 (en) * 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
JPH08506343A (ja) * 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
IL122335A0 (en) 1998-04-05
CZ392797A3 (cs) 1999-04-14
OA10639A (en) 2002-09-17
SK166097A3 (en) 1999-06-11
EP0832091B1 (en) 2004-01-14
EA199800009A1 (ru) 1998-06-25
DE69631330D1 (de) 2004-02-19
HUP9802193A2 (hu) 1999-05-28
DE69631330T2 (de) 2004-10-28
PL323904A1 (en) 1998-04-27
EP0832091A1 (en) 1998-04-01
MX9709859A (es) 1998-08-30
CN1190401A (zh) 1998-08-12
BG102163A (en) 1998-10-30
JPH11507387A (ja) 1999-06-29
WO1996040705A1 (en) 1996-12-19
NO975585L (no) 1998-02-05
US5674998A (en) 1997-10-07
AU6178396A (en) 1996-12-30
KR19990022740A (ko) 1999-03-25
ATE257841T1 (de) 2004-01-15
HUP9802193A3 (en) 1999-10-28
NO975585D0 (no) 1997-12-03
CA2220642A1 (en) 1996-12-19
AP9701165A0 (en) 1998-01-31
TR199701539T1 (xx) 1998-04-21
IS4621A (is) 1997-11-26

Similar Documents

Publication Publication Date Title
BR9609013A (pt) Análogo de nucleosìdeos, e, composto.
ATE282628T1 (de) Oral aktive adenosinkinase-inhibitoren
ATE296309T1 (de) Wasserlösliche adenosin kinase inhibitoren
EP2011499A3 (en) Pyrrolo[2,3d]Pyrimidine compositions and their use
DE69427862D1 (de) K-252a derivate, die neurotrophin-induzierte aktivität erhöhen
IL112539A (en) Chloropyrimidine intermediates for preparing-2-aminopurine nucleoside analogues and their preparation
ES2071486T3 (es) Derivado de la 5h-pirrolo(3,4-b)pirazina opticamente activa, su preparacion y las composiciones farmaceuticas que le contienen.
SE9701398D0 (sv) Novel compounds
IT8547852A0 (it) Ciclosporine,processi per la loro preparazione,uso farmaceutico delle stesse e composizioni farmaceutiche che le contengono
FI956168A0 (fi) Uudet kemialliset yhdisteet, joilla on PDE-IV:ää inhiboivaa aktiivisuutta
ES2179193T3 (es) Combinaciones sinergicas de zidovudina, 1592u89 y 3tc.
FI913236A (fi) 9-purinylfosfonsyraderivat.
IE900275L (en) Antivirals and methods of increasing the antiviral activity¹of azt
BR9814080A (pt) Uso de compostos para atividade anti-prurìtica
BR0304963A (pt) Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
ES2111960T3 (es) Analogos de nucleosidos bloqueados conformacionalmente.
PT874839E (pt) Derivados de furano- e tiofeno-carbotioamidas sua preparacao e sua utilizacao como inibidores da replicacao do hiv-1 e de mutantes do hiv-1
PT1044203E (pt) Derivados epimericos 3' do k-252a
FI950533A0 (fi) Seco-nukleosidien liponulkeotidit, niiden valmistaminen sekä niiden käyttö virusten vastaisina lääkkeinä
ATE72122T1 (de) Antivirale mischungen.
MX9303985A (es) Nucleosidos terapeuticos.
GB9506644D0 (en) Preparation of nucleoside analogues
ATE334672T1 (de) Ginkolide zur hemmung der membranexpression
ECSP961863A (es) Compuesto activo farmacologicamente
MX9709788A (es) Analogos de nucleotidos para tratamiento topico de enfermedades proliferativas de la piel.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A,7A,8A E 9A ANUIDADES.